Defining the clinical course of multiple sclerosis

The 2013 revisions

Fred D. Lublin, Stephen C. Reingold, Jeffrey A. Cohen, Gary R. Cutter, Per Soelberg Sørensen, Alan J. Thompson, Jerry S. Wolinsky, Laura J. Balcer, Brenda Banwell, Frederik Barkhof, Bruce Bebo, Peter Calabresi, Michel Clanet, Giancarlo Comi, Robert J. Fox, Mark S. Freedman, Andrew D. Goodman, Matilde Inglese, Ludwig Kappos, Bernd C. Kieseier & 12 others John A. Lincoln, Catherine Lubetzki, Aaron E. Miller, Xavier Montalban, Paul W. O'Connor, John Petkau, Carlo Pozzilli, Richard A. Rudick, Maria Pia Sormani, Olaf Stüve, Emmanuelle Waubant, Chris H. Polman

Research output: Contribution to journalArticle

Abstract

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

Original languageEnglish (US)
Pages (from-to)278-286
Number of pages9
JournalNeurology
Volume83
Issue number3
DOIs
StatePublished - Jul 15 2014

Fingerprint

Multiple Sclerosis
Phenotype
Clinical Trials
Advisory Committees
Disease Progression
Consensus
Decision Making
Biomarkers
Communication
Pathology
Recurrence
Imaging

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., ... Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology, 83(3), 278-286. https://doi.org/10.1212/WNL.0000000000000560

Defining the clinical course of multiple sclerosis : The 2013 revisions. / Lublin, Fred D.; Reingold, Stephen C.; Cohen, Jeffrey A.; Cutter, Gary R.; Sørensen, Per Soelberg; Thompson, Alan J.; Wolinsky, Jerry S.; Balcer, Laura J.; Banwell, Brenda; Barkhof, Frederik; Bebo, Bruce; Calabresi, Peter; Clanet, Michel; Comi, Giancarlo; Fox, Robert J.; Freedman, Mark S.; Goodman, Andrew D.; Inglese, Matilde; Kappos, Ludwig; Kieseier, Bernd C.; Lincoln, John A.; Lubetzki, Catherine; Miller, Aaron E.; Montalban, Xavier; O'Connor, Paul W.; Petkau, John; Pozzilli, Carlo; Rudick, Richard A.; Sormani, Maria Pia; Stüve, Olaf; Waubant, Emmanuelle; Polman, Chris H.

In: Neurology, Vol. 83, No. 3, 15.07.2014, p. 278-286.

Research output: Contribution to journalArticle

Lublin, FD, Reingold, SC, Cohen, JA, Cutter, GR, Sørensen, PS, Thompson, AJ, Wolinsky, JS, Balcer, LJ, Banwell, B, Barkhof, F, Bebo, B, Calabresi, P, Clanet, M, Comi, G, Fox, RJ, Freedman, MS, Goodman, AD, Inglese, M, Kappos, L, Kieseier, BC, Lincoln, JA, Lubetzki, C, Miller, AE, Montalban, X, O'Connor, PW, Petkau, J, Pozzilli, C, Rudick, RA, Sormani, MP, Stüve, O, Waubant, E & Polman, CH 2014, 'Defining the clinical course of multiple sclerosis: The 2013 revisions', Neurology, vol. 83, no. 3, pp. 278-286. https://doi.org/10.1212/WNL.0000000000000560
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et al. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 2014 Jul 15;83(3):278-286. https://doi.org/10.1212/WNL.0000000000000560
Lublin, Fred D. ; Reingold, Stephen C. ; Cohen, Jeffrey A. ; Cutter, Gary R. ; Sørensen, Per Soelberg ; Thompson, Alan J. ; Wolinsky, Jerry S. ; Balcer, Laura J. ; Banwell, Brenda ; Barkhof, Frederik ; Bebo, Bruce ; Calabresi, Peter ; Clanet, Michel ; Comi, Giancarlo ; Fox, Robert J. ; Freedman, Mark S. ; Goodman, Andrew D. ; Inglese, Matilde ; Kappos, Ludwig ; Kieseier, Bernd C. ; Lincoln, John A. ; Lubetzki, Catherine ; Miller, Aaron E. ; Montalban, Xavier ; O'Connor, Paul W. ; Petkau, John ; Pozzilli, Carlo ; Rudick, Richard A. ; Sormani, Maria Pia ; Stüve, Olaf ; Waubant, Emmanuelle ; Polman, Chris H. / Defining the clinical course of multiple sclerosis : The 2013 revisions. In: Neurology. 2014 ; Vol. 83, No. 3. pp. 278-286.
@article{abffdfb2cb494636b0084c7d9eebb133,
title = "Defining the clinical course of multiple sclerosis: The 2013 revisions",
abstract = "Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.",
author = "Lublin, {Fred D.} and Reingold, {Stephen C.} and Cohen, {Jeffrey A.} and Cutter, {Gary R.} and S{\o}rensen, {Per Soelberg} and Thompson, {Alan J.} and Wolinsky, {Jerry S.} and Balcer, {Laura J.} and Brenda Banwell and Frederik Barkhof and Bruce Bebo and Peter Calabresi and Michel Clanet and Giancarlo Comi and Fox, {Robert J.} and Freedman, {Mark S.} and Goodman, {Andrew D.} and Matilde Inglese and Ludwig Kappos and Kieseier, {Bernd C.} and Lincoln, {John A.} and Catherine Lubetzki and Miller, {Aaron E.} and Xavier Montalban and O'Connor, {Paul W.} and John Petkau and Carlo Pozzilli and Rudick, {Richard A.} and Sormani, {Maria Pia} and Olaf St{\"u}ve and Emmanuelle Waubant and Polman, {Chris H.}",
year = "2014",
month = "7",
day = "15",
doi = "10.1212/WNL.0000000000000560",
language = "English (US)",
volume = "83",
pages = "278--286",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Defining the clinical course of multiple sclerosis

T2 - The 2013 revisions

AU - Lublin, Fred D.

AU - Reingold, Stephen C.

AU - Cohen, Jeffrey A.

AU - Cutter, Gary R.

AU - Sørensen, Per Soelberg

AU - Thompson, Alan J.

AU - Wolinsky, Jerry S.

AU - Balcer, Laura J.

AU - Banwell, Brenda

AU - Barkhof, Frederik

AU - Bebo, Bruce

AU - Calabresi, Peter

AU - Clanet, Michel

AU - Comi, Giancarlo

AU - Fox, Robert J.

AU - Freedman, Mark S.

AU - Goodman, Andrew D.

AU - Inglese, Matilde

AU - Kappos, Ludwig

AU - Kieseier, Bernd C.

AU - Lincoln, John A.

AU - Lubetzki, Catherine

AU - Miller, Aaron E.

AU - Montalban, Xavier

AU - O'Connor, Paul W.

AU - Petkau, John

AU - Pozzilli, Carlo

AU - Rudick, Richard A.

AU - Sormani, Maria Pia

AU - Stüve, Olaf

AU - Waubant, Emmanuelle

AU - Polman, Chris H.

PY - 2014/7/15

Y1 - 2014/7/15

N2 - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

AB - Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

UR - http://www.scopus.com/inward/record.url?scp=84905819646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905819646&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000000560

DO - 10.1212/WNL.0000000000000560

M3 - Article

VL - 83

SP - 278

EP - 286

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -